<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03233646</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00082598</org_study_id>
    <nct_id>NCT03233646</nct_id>
  </id_info>
  <brief_title>OCTA in Mild Cognitive Impairment and Alzheimer's Disease</brief_title>
  <official_title>Evaluating the Retinal Microvasculature in Mild Cognitive Impairment and Alzheimer's Disease Using Optical Coherence Tomography Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimerâ€™s Drug Discovery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to develop and evaluate biomarkers using non-invasive optical coherence
      tomography angiography (OCTA) to assess the structure and function of the retinal
      microvasculature in persons with mild cognitive impairment (MCI) and Alzheimer's Disease
      (AD), Parkinson's Disease (PD) or other neurodegenerative disease, multiple sclerosis, and
      Huntington's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a multidisciplinary approach, this study aims to yield new insight into the vascular
      pathophysiology of mild cognitive impairment (MCI) and Alzheimer's Disease (AD) Parkinson's
      Disease (PD) or other neurodegenerative disease. The investigators propose to develop and
      evaluate biomarkers using non-invasive optical coherence tomography angiography (OCTA) to
      assess the structure and function of the retinal microvasculature in persons with MCI and AD,
      PD or other neurodegenerative disease multiple sclerosis, and Huntington's disease..

      The investigators hypothesize that microvascular network alterations in the retina mirror and
      possibly precede changes in the cerebral microcirculation seen in these diseases. Using
      advanced image analysis, the investigators aim to evaluate markers of reduced capillary blood
      flow and non-perfusion in the superficial and deep retinal vascular plexuses and
      choriocapillaris imaged using OCTA, in a resolution not previously possible, that would
      complement already established retinal structural markers and increase their sensitivity and
      specificity in the early detection of MCI and AD, PD, multiple sclerosis, and Huntington's
      disease. or other neurodegenerative disease.

      This study looks to provide a proof of concept for OCTA-based retinal microvascular
      biomarkers as an effective screening tool in cognitive aging.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Foveal avascular zone</measure>
    <time_frame>12 months</time_frame>
    <description>Differences in Foveal avascular zone size</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vessel Density</measure>
    <time_frame>12 months</time_frame>
    <description>Differences in Superficial and Deep Capillary Plexus Vessel Density</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Choroidal Thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Differences in subfoveal choroidal thickness between the two groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Retinal Vascular</condition>
  <condition>Parkinson Disease</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Huntington Disease</condition>
  <condition>Neuro-Degenerative Disease</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 patients with MCI and/or AD, PD, multiple sclerosis, and Huntington's disease.or other neuro-degenerative disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controls will be recruited from the relatives/attendants of the patients , or will be patients themselves, and will not have a diagnosis of MCI/AD/PD/MS/Huntington's Disease or other neuro-degenerative disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Retinal Imaging</intervention_name>
    <description>Non-invasive OCTA scan of retina</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with neurodegenerative disease (MCI/ADPD/MS/HD)

          -  Age-gender-race-matched controls.

        Exclusion Criteria:

          -  History of known or suspected diagnosis of non-AD

          -  Associated dementia

          -  Diabetes mellitus

          -  Inability to cooperate with or complete testing

          -  Evidence of glaucoma

          -  Macular degeneration

          -  Other neurologic or age-related ocular conditions that would impact OCTA segmentation.
             -Eyes that have had intraocular surgery, other than cataract surgery, will be excluded

          -  If two eyes satisfy the inclusion criteria, both eyes will be included in the study.
             If one eye satisfies the inclusion criteria, the eye that qualifies will be included
             in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dilraj Grewal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon Fekrat, MD</last_name>
    <role>Study Director</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dilraj Grewal, MD</last_name>
    <phone>919-684-4458</phone>
    <email>dilraj.grewal@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dilraj Grewal, MD</last_name>
      <phone>919-684-4458</phone>
      <email>dilraj.grewal@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Sharon Fekrat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Burke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCT angiography</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Vessel Density</keyword>
  <keyword>Superficial Capillary Plexus</keyword>
  <keyword>retinal microvasculature</keyword>
  <keyword>OCTA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Huntington Disease</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

